ReviewFrontiers in pediatrics2026
Biochemical markers of endothelial injury in children with obesity-from adhesion molecules to novel endothelium-specific biomarkers.
Review in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Childhood obesity is no longer only a metabolic condition but an early vascular disease. Subclinical endothelial dysfunction develops long before overt cardiovascular complications and may contribute to the later emergence of atherosclerosis and hypertension. Detecting these early alterations remains a major challenge in pediatric care. Methods: This mini review integrates current evidence on circulating biochemical markers of endothelial injury in children with obesity, focusing on markers reflecting endothelial activation, hemostatic imbalance, and vascular dysfunction. Results: Multiple biomarkers are altered in pediatric obesity. Soluble adhesion molecules reflect early endothelial activation and low-grade inflammation. Hemostatic markers indicate a shift toward a prothrombotic state. Dysregulation of the NO-eNOS-ADMA axis contributes to reduced nitric oxide bioavailability and impaired vascular function. Emerging endothelium-specific biomarkers, including endocan and syndecan-1, offer greater specificity and appear to capture early vascular injury more sensitively than traditional inflammatory markers. Indirect markers further link metabolic, inflammatory, and oxidative pathways. Conclusions: Endothelial dysfunction represents an early, clinically silent but potentially reversible stage of obesity-related vascular disease in children. A multimarker approach may improve early risk identification and better reflect the complexity of underlying mechanisms. These findings support a shift toward earlier, multidisciplinary cardiovascular risk assessment in pediatric obesity and highlight the need for prospective studies to translate biomarkers into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.